ANDA 75353, held by Teva. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 75353 (Doxazosin Mesylate), held by Teva, was first approved by FDA on Jan 12, 2001, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 12, 2001 | Original application | Approved |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Feb 13, 2004 | Supplement 1Labeling | Approved | None posted |
| Jan 12, 2001 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters